Evercore ISI Group Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $260
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Liisa Bayko maintains an Outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $210 to $260.
June 25, 2024 | 2:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group analyst Liisa Bayko maintains an Outperform rating on Alnylam Pharmaceuticals and raises the price target from $210 to $260.
The raised price target from $210 to $260 and the maintained Outperform rating by Evercore ISI Group are positive signals for investors, likely leading to a short-term increase in ALNY's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100